Fraunhofer Institute for Translational Medicine and Pharmacology ITMP

Fraunhofer CIMD in leading role in new EU-IMI project "HIPPOCRATES" to promote early detection and improve outcome of psoriatic arthritis.

Funded by the Innovative Medicines Initiative (IMI), Fraunhofer ITMP, IAIS and IGD, as part of the Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD, are collaborating with 25 European partners to research an insufficiently understood disease that affects millions of people.

Fraunhofer ITMP is one of the core institutes of the Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD. The annual "Day of Immune Research" provides insights into the work of the cluster and serves as an information and exchange platform for current topics in the field of immune-mediated diseases and immune research. 

The 3rd Day of Immune Research will take place in Leipzig on November 12, 2021. 

The Fraunhofer CIMD Winter School will take place from October 5-8, 2021 in Leipzig as part of the Fraunhofer CIMD Young Investigator Program. This event is primarily aimed at PhD students, young postdocs and project members from the Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD, of which Fraunhofer ITMP is a core institute.

Fraunhofer launches a new research project, the „e-Pille“, designed to streamline the formulation of new drugs for oral delivery. In this project Fraunhofer scientists from three Institutes (Fraunhofer ITMP, EMFT and IZM) are pursuing the goal of developing an electronic capsule roughly the size of a multivitamin capsule by integrating innovative techniques that allow precise, accurate and reproducible dosage and release of a drug.

After the recent successes in vaccine development, drug development against the COVID-19 disease is moving into focus. Fraunhofer ITMP is applying Drug Repurposing strategies in various projects focusing on SARS-CoV-2. Repurposing strategies use substances that have undergone clinical testing in other disease indications and investigate their effect against COVID-19. These strategies can not only identify effective substances for different stages of the disease, but also contribute to a better understanding of the mechanisms of action of this disease. 

Fraunhofer ITMP is a temporary project partner for the additional research project focussing on the development of inhalable drugs to combat SARS-CoV-2, started in May 2020 within the frame of the international iCAIR® consortium. The iCAIR® research team, coordinated by Fraunhofer ITEM, can already report promising results for this project.